General Overview:

CJC-1295 (without DAC) combined with Ipamorelin is a research peptide blend studied for its ability to support the body’s natural growth hormone release. CJC-1295 without DAC acts as a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin works as a selective growth hormone secretagogue.

Together, researchers examine this combination for its potential to encourage more consistent growth hormone pulses. In experimental settings, scientists explore its effects on recovery, body composition, and related metabolic processes.

Technical Overview

CJC-1295 (No DAC) + Ipamorelin is a research peptide blend formulated for laboratory investigation involving growth hormone secretagogue pathways and peptide interaction studies. This combination is commonly examined in controlled research settings for its role in supporting analysis of pulsatile growth hormone signaling and receptor-specific activity.

CJC-1295 (No DAC) is a modified growth hormone releasing hormone (GHRH) analog designed for research related to pituitary stimulation mechanisms, while Ipamorelin is a selective pentapeptide studied for its interaction with growth hormone secretagogue receptors (GHS-R). When combined, these compounds are frequently utilized in peptide research protocols exploring synergistic signaling behavior under controlled experimental conditions.

The blend is typically synthesized using established peptide manufacturing methods and purified through HPLC to achieve high analytical purity suitable for research and assay applications.

Specifications

Compound Name: CJC-1295 (No DAC) + Ipamorelin Available Strengths: 10 mg Format: Research Peptide Blend Appearance: Lyophilized Peptide Powder Purity: ≥ 99% (HPLC Verified) Storage: −20°C recommended

Notice

This compound is provided strictly as a reference reagent for scientific and laboratory investigation. Research Only. Not for Human Use.